SCHEMBL5470128

SCHEMBL5470128

Cc1ccc(SCC(=O)Nc2ncc3c(n2)-c2ccccc2CC3)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.69
MAPT P10636 5/20 0.69
ALDH1A1 P00352 4/20 0.69
L3MBTL1 Q9Y468 4/20 0.69
KMT2A Q03164 4/20 0.69
HTT P42858 4/20 0.69
MEN1 O00255 3/20 0.69
POLB P06746 3/20 0.69
KPNA2 P52292 1/20 0.69
LMNA P02545 4/20 0.68
GAA P10253 3/20 0.68
CYP1A2 P05177 4/20 0.57
CYP3A4 P08684 4/20 0.57
CYP2C19 P33261 3/20 0.57
CYP2C9 P11712 2/20 0.53
CYP2D6 P10635 1/20 0.53
HPGD P15428 2/20 0.52
RCE1 Q9Y256 1/20 0.52
DUSP10 Q9Y6W6 1/20 0.50
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468199 0.82 KDM4E (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL5462701 0.81 KDM4E (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL5472904 0.74 CYP1A2 (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL11296578 0.72 LMNA (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL12330249 0.70 CYP1A2 (0.62) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL29929637 0.70 CYP1A2 (0.66) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL4986074 0.70 CYP1A2 (0.66) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL5469070 0.70 KDM4E (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL5462657 0.70 KDM4E (1.00) KDM4EMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL13373267 0.69 CYP1A2 (0.58) KDM4EMAPTALDH1A1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR KDM4E 2371/4885MAPT 4503/4885ALDH1A1 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.